Nalagenetics
Business Services · Indonesia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Jl. Banjarsari Lantai 1 1, Cilandak Ja...Website
www.nalagenetics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Nalagenetics
Nalagenetics is a Singapore-based biotech company dedicated to reducing adverse drug reactions and increase prescription efficacy through genetic testing for local Asian populations in Singapore, Indonesia and beyond. By studying how certain DNA characteristics affect drug responses, the company aims to develop genetic tests that are easier to understand, more affordable, and localized for Asian physicians and patients. The Nalagenetics team consists of passionate and driven engineers, scientists, and healthcare professionals dedicated to improving the lives of people throughout Southeast Asia. They just got pre seed funding from East Ventures.Explore more
Nalagenetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nalagenetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nalagenetics recently announced quarterly report
Check out if Nalagenetics is spiking on competitors!
Check if Nalagenetics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Nalagenetics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Nalagenetics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Nalagenetics had a recent Job posting/layoffs
Product Launch: Get notified when Nalagenetics launches new products
Congratulate Masked Content for being promoted to Masked Content at Nalagenetics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Nalagenetics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nalagenetics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nalagenetics.
Nalagenetics financials insights
Gather financial insights about Nalagenetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$12.6M
Other Financing Round
$1M
Nalagenetics Tech Stack
A closer look at the technologies used by Nalagenetics
See more technologies
Most Recent Scoops
Hiring Plans
Nalagenetics is hiring in Marketing for the first time in 12 months.
Hiring Plans
Hiring Plans
Nalagenetics has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Hiring Plans
Nalagenetics has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Nalagenetics News & Media
Raffles Medical Group and NalaGenetics Provide Pre-emptive Genetic Testing for Adverse Drug Reactions
Raffles is the first hospital in Singapore to provide pre-emptive pharmacogenomics testing protocol Aims to reduce side effects due to inappropriate medications SINGAPORE, Oct. 7, 2022 /PRNewswire/ -- Raffles Medical Group (RMG) is collaborating with biotech start-up NalaGenetics to offer pre-emptive pharmacogenomics testing at its hospital. It is the first hospital in Singapore to provide such a service. Pharmacogenomics is the study of how genes affect a person's response to medication. Pre-emNalagenetics obtains CE Mark for its pharmacogenomics software, Nala Clinical Decision Support™ Module- PGx Core
SINGAPORE, May 31, 2022 /PRNewswire/ -- Nalagenetics has just completed CE-marking for one of the reporting modules of its Clinical Decision Support (CDS) software. The registration enables its software to be marketed in Europe and support further approval in Southeast Asia, where it aims to gain market share. Nala Clinical Decision Support™ Module - PGx Core is a companion software to its qPCR kit, Nala PGx Core(R) , which genotypes top pharmacogenes to help providers runMGI announces partnership with Nalagenetics to advance personalized medicine
The partnership will address some critical issues in pharmacogenetic assay through sequencing workflows improvement SINGAPORE, April 19, 2022 /PRNewswire/ -- MGI, a company committed to being a world-leading life science innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low coverage whole genome sequencing for risk prediction and population genomics through optimizing Next Generation Sequencing (NGS) workflow based on MGI sequencing devices and products*. The collabSingapore biotech firm Nalagenetics raises $12.6M Series A funding co-led by Intudo ...
Nalagenetics announced Friday the closing of a $12.6 million Series A round of financing co-led by Intudo Ventures and Vulcan Capital. The round also saw participation from strategic investors, including Singapore-based Diagnostics Development Hub (DxD Hub) through the Agency for Science, Technology and Research’s (A*STAR) A*ccelerate Technologies Pte Ltd, and Indonesia-based Dexa International, Diagnos Laboratories among others. With this round of financing, Nalagenetics plans to focus on produ
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nalagenetics
Sign Up For FreeTo access detailed company insights
Nalagenetics is a Singapore-based biotech company dedicated to reducing adverse drug reactions and increase prescription efficacy through genetic testing for local Asian populations in Singapore, Indonesia and beyond. By studying how certain DNA characteristics affect drug responses, the company aims to develop genetic tests that are easier to unde... Read More
